Health Dictionary Find a Doctor

Bladder cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]

Overview

The predominant therapy for bladder cancer is surgical resection. Adjunctive chemotherapy, radiation therapy, and immunotherapy may be required.

Medical Therapy

Immunotherapy

  • Immunotherapy is a type of biological therapy that uses the immune system to help destroy cancer cells.[1]
  • Bacillus Calmette–Guérin (BCG)
  • Immunotherapy by intravesicular delivery of Bacillus Calmette–Guérin (BCG) is often used to treat and prevent the recurrence of superficial tumors.[2]
  • BCG is a vaccine against tuberculosis that is prepared from attenuated live Mycobacterium bovis, that has lost its virulence in humans. BCG immunotherapy is effective in up to 2/3 of the cases at this stage, and in randomized trials has been shown to be superior to standard chemotherapy.[3]
  • The mechanism by which BCG prevents recurrence is unknown, but the presence of bacteria in the bladder may trigger a localized immune reaction which clears residual cancer cells.

Chemotherapy

  • During intravesical chemotherapy, the drugs are placed into the bladder through a urinary catheter.[4][5]
  • Intravesical chemotherapy may be given instead of BCG or if the bladder cancer doesn’t respond to BCG.[6]
  • Mitomycin is the drug most often used in intravesical chemotherapy.[7][8]
  • Systemic chemotherapy
  • During systemic chemotherapy, the drugs are given intravenously.
  • Systemic chemotherapy may be a treatment option for bladder cancer that has spread to other tissues near the bladder and bladder cancer that has spread to other parts of the body.[9]
  • Chemotherapy is recommended before a radical cystectomy (called neoadjuvant chemotherapy) for many people with bladder cancer that has grown into the muscle layer of the bladder wall. It is also often given after a radical cystectomy (called adjuvant chemotherapy) to people with high-risk features such as cancer that has spread to lymph nodes.[10]

Radiation therapy

  • Palliative radiation therapy may be given to relieve symptoms caused by advanced bladder cancer.[13]

References

  1. Ghahestani SM, Shakhssalim N (2009). “Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review”. Urol J. 6 (3): 149–56. PMID 19711266.
  2. Alexandroff AB, Jackson AM, O’Donnell MA, James K (May 1999). “BCG immunotherapy of bladder cancer: 20 years on”. Lancet. 353 (9165): 1689–94. doi:10.1016/S0140-6736(98)07422-4. PMID 10335805.
  3. Lamm, Donald L.; Blumenstein, Brent A.; Crawford, E. David; Montie, James E.; Scardino, Peter; Grossman, H. Barton; Stanisic, Thomas H.; Smith Jr, Joseph A.; Sullivan, Jerry; Sarosdy, Michael F.; Crissman, John D.; Coltman, Charles A. (1991). “A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder”. New England Journal of Medicine. 325 (17): 1205–9. doi:10.1056/NEJM199110243251703. PMC 1164610. PMID 1922207.
  4. Bladder Cancer. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/bladder/treatment/?region=ab Accessed on October, 7 2015
  5. Porten SP, Leapman MS, Greene KL (2015). “Intravesical chemotherapy in non-muscle-invasive bladder cancer”. Indian J Urol. 31 (4): 297–303. doi:10.4103/0970-1591.166446. PMC 4626913. PMID 26604440.
  6. Shen Z, Shen T, Wientjes MG, O’Donnell MA, Au JL (July 2008). “Intravesical treatments of bladder cancer: review”. Pharm. Res. 25 (7): 1500–10. doi:10.1007/s11095-008-9566-7. PMC 2440939. PMID 18369709.
  7. Volpe A, Racioppi M, D’Agostino D, Cappa E, Filianoti A, Bassi PF (June 2010). “Mitomycin C for the treatment of bladder cancer”. Minerva Urol Nefrol. 62 (2): 133–44. PMID 20562793.
  8. Williams SK, Hoenig DM, Ghavamian R, Soloway M (April 2010). “Intravesical therapy for bladder cancer”. Expert Opin Pharmacother. 11 (6): 947–58. doi:10.1517/14656561003657145. PMID 20205607.
  9. Rose TL, Milowsky MI (May 2016). “Improving Systemic Chemotherapy for Bladder Cancer”. Curr Oncol Rep. 18 (5): 27. doi:10.1007/s11912-016-0512-2. PMID 26984414.
  10. Teply BA, Kim JJ (2014). “Systemic therapy for bladder cancer – a medical oncologist’s perspective”. J Solid Tumors. 4 (2): 25–35. doi:10.5430/jst.v4n2p25. PMC 4232954. PMID 25404954.
  11. Konski A, Feigenberg S, Chow E (April 2005). “Palliative radiation therapy”. Semin. Oncol. 32 (2): 156–64. PMID 15815960.
  12. Kaufman DS, Shipley WU, Althausen AF (February 1992). “Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing”. Hematol. Oncol. Clin. North Am. 6 (1): 179–94. PMID 1556049.
  13. Byun SJ, Kim JH, Oh YK, Kim BH (December 2015). “Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer”. Radiat Oncol J. 33 (4): 294–300. doi:10.3857/roj.2015.33.4.294. PMC 4707212. PMID 26756029.

Template:WH Template:WS

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH